|

XPO1 inhibitor Clinical Trials

2 actively recruiting trials

No change since May 2026

Also known as: COPL

Pipeline

Phase 2: 2

Top Sponsors

  • Chinese PLA General Hospital1
  • Beijing Tongren Hospital1

Indications

  • Cancer2
  • NK/T-cell Lymphoma1
  • Primary Central Nervous System Lymphoma (PCNSL)1
  • Advanced Lymphoma1
  • Newly Diagnosed1

Other2 trials

Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma
Phase 2
Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.